- Home
- PSHG vs TXMD Comparison
PSHG vs TXMD Comparison
Compare PSHG & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- TXMD
- Stock Information
- Founded
- PSHG 2010
- TXMD 2008
- Country
- PSHG Greece
- TXMD United States
- Employees
- PSHG N/A
- TXMD N/A
- Industry
- PSHG Marine Transportation
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- TXMD Health Care
- Exchange
- PSHG Nasdaq
- TXMD Nasdaq
- Market Cap
- PSHG 20.8M
- TXMD 17.1M
- IPO Year
- PSHG N/A
- TXMD N/A
- Fundamental
- Price
- PSHG $1.81
- TXMD $1.18
- Analyst Decision
- PSHG Strong Buy
- TXMD
- Analyst Count
- PSHG 1
- TXMD 0
- Target Price
- PSHG $6.50
- TXMD N/A
- AVG Volume (30 Days)
- PSHG 185.9K
- TXMD 69.2K
- Earning Date
- PSHG 07-24-2025
- TXMD 08-11-2025
- Dividend Yield
- PSHG N/A
- TXMD N/A
- EPS Growth
- PSHG N/A
- TXMD N/A
- EPS
- PSHG 1.58
- TXMD N/A
- Revenue
- PSHG $86,407,000.00
- TXMD $1,841,000.00
- Revenue This Year
- PSHG N/A
- TXMD $427.09
- Revenue Next Year
- PSHG $23.25
- TXMD N/A
- P/E Ratio
- PSHG $1.18
- TXMD N/A
- Revenue Growth
- PSHG N/A
- TXMD 53.55
- 52 Week Low
- PSHG $1.31
- TXMD $0.70
- 52 Week High
- PSHG $2.34
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- PSHG 53.83
- TXMD 47.25
- Support Level
- PSHG $1.75
- TXMD $1.11
- Resistance Level
- PSHG $2.02
- TXMD $1.22
- Average True Range (ATR)
- PSHG 0.15
- TXMD 0.09
- MACD
- PSHG -0.01
- TXMD 0.00
- Stochastic Oscillator
- PSHG 29.33
- TXMD 42.31
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.